Medical Assistance for the Procreation and Risk of Thrombosis.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

129 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-02-02

Study Completion Date

2016-11-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims at evaluating clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation.

Secondary outcomes are : 1) to describe the incidence and risk factors of arterial and venous thrombosis in women undergoing assisted reproductive technology and 2)to identify the incidence and risk factors for ovarian hyperstimulation syndrome in these women

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of an Antithrombotic Therapeutic Strategy in Pregnant Women

NCT00745212

Placental Vascular Pathologies Venous Thromboembolism Diseases

COMPLETED

Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure

NCT03206372

Venous Thromboembolic Disease

RECRUITING

Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor

NCT07342127

Factor V Leiden Heterozygous Mutation Factor II Heterozygous Mutation Pregnancy +1 more

NOT_YET_RECRUITING

Risk, Predictors, Impact and Outcome of Anticoagulation-associated Abnormal Menstrual Bleeding

NCT04748393

Venous Thromboembolism

TERMINATED

Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)

NCT01357941

Venous Thromboembolism Deep Vein Thrombosis Pulmonary Embolism

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All women undergoing an assisted reproductive tecnology in order to receive an in vitro fertilization in French centers will be included in the study. These women will be followed up until 12 months after ovarian stimulation if they get pregnant or until 3 months if the stimulation does not lead to pregnancy. Risk factors for thrombosis and ovarian hyperstimulation syndrome will be collected in each woman. At each visit, women will be asked whether arterial and/or venous thrombosis had occured.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Hyperstimulation Syndrome Cardiovascular Diseases Embolism and Thrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Women undergoing ART

Observation of the incidence of venous and arterial thrombosis following ovarian stimulation

ovarian stimulation

Intervention Type OTHER

evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ovarian stimulation

evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All women undergoing ovarian stimulation in order to receive in vitro fertilization

Exclusion Criteria

* Age\<18 years
* Women refusing to particpate in the study
* No health coverage
* Women under guardianship
* Women receiving therapeutic doses of anticoagulation

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No